• Akorn, Inc. has acquired from Santen the New Drug Aplication and all rights to the glaucoma drug Betimol (timolol ophthalmic solution, 0.25% and 0.5%). The company plans to begin shipping Betimol in the first quarter of 2014.

    This acquisition is expected to add $8 million to $9 million in revenue to Akorn’s coffers this year and approximately $0.03 to $0.04 of adjusted net income per diluted share.